Krystal Biotech Inc (KRYS)
182.29
+4.19
(+2.35%)
USD |
NASDAQ |
Nov 21, 16:00
182.47
+0.18
(+0.10%)
After-Hours: 20:00
Krystal Biotech Net Income (Quarterly): 27.18M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 27.18M |
| June 30, 2024 | 15.57M |
| March 31, 2024 | 0.932M |
| December 31, 2023 | 8.692M |
| September 30, 2023 | 80.75M |
| June 30, 2023 | -33.21M |
| March 31, 2023 | -45.30M |
| December 31, 2022 | -32.05M |
| September 30, 2022 | -29.85M |
| June 30, 2022 | -28.11M |
| March 31, 2022 | -49.96M |
| December 31, 2021 | -21.81M |
| September 30, 2021 | -15.59M |
| June 30, 2021 | -16.36M |
| March 31, 2021 | -15.81M |
| December 31, 2020 | -10.38M |
| September 30, 2020 | -9.61M |
| Date | Value |
|---|---|
| June 30, 2020 | -6.833M |
| March 31, 2020 | -5.341M |
| December 31, 2019 | -5.357M |
| September 30, 2019 | -4.272M |
| June 30, 2019 | -5.348M |
| March 31, 2019 | -4.111M |
| December 31, 2018 | -3.708M |
| September 30, 2018 | -2.755M |
| June 30, 2018 | -2.276M |
| March 31, 2018 | -2.15M |
| December 31, 2017 | -1.393M |
| September 30, 2017 | -5.273M |
| June 30, 2017 | -0.759M |
| March 31, 2017 | -0.494M |
| December 31, 2016 | -0.627M |
| September 30, 2016 | -0.322M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-49.96M
Minimum
Mar 2022
80.75M
Maximum
Sep 2023
-9.623M
Average
-12.99M
Median
Net Income (Quarterly) Benchmarks
| Bioventus Inc | -4.824M |
| ADMA Biologics Inc | 35.91M |
| Alnylam Pharmaceuticals Inc | -111.57M |
| Amicus Therapeutics Inc | -6.729M |
| Rhythm Pharmaceuticals Inc | -43.64M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 83.84M |
| Total Expenses (Quarterly) | 48.91M |
| EPS Diluted (Quarterly) | 0.91 |
| Enterprise Value | 4.654B |
| Gross Profit Margin (Quarterly) | 92.03% |
| Profit Margin (Quarterly) | 32.42% |
| Earnings Yield | 0.98% |
| Operating Earnings Yield | 1.21% |
| Normalized Earnings Yield | 1.595 |